Mirum reports a 0.98-point itch improvement over placebo in LIVMARLI's Phase 3 EXPAND trial and plans a U.S. filing in the ...

Strategy bought 250 bitcoin for US$21.5 million and separately repurchased US$192.4 million of Stretch preferred stock during ...

Bristol Myers Squibb says 60 mg admilparant met the Phase 3 IPF endpoint, while 120 mg missed significance; companion data ...

ANI Pharmaceuticals says its 108-patient SYNCHRONICITY study met both six-month endpoints, with vision and retinal ...

China approved CAMCEVI 42 mg for advanced prostate cancer, with GenSci responsible for commercialization under an exclusive ...

Maas reports A$373M paid against A$1.1B of Firmus work orders, with completion expected by end-2027 as its customer seeks ...

Tialis Essential IT plc wins a five-year £7.6M utilities contract and renews a public-sector agreement generating about £1.2M ...

Ballard Mining has A$45 million in placement commitments at A$0.66 a share, plus a retail offer to fund Mt Ida drilling and ...

InnoCare says China approved its ICP-B161 IND, making it the fifth candidate to enter clinical development in 2026; ...

Nordic Resources reports 1.52 million gold-equivalent ounces at Kopsa, with 86 per cent measured and indicated and further ...

Cobre reports a 62.86 per cent interest in Sierra Atacama after exercising a control option for approximately US$12 million ...

Roche says vamikibart gains lasted through week 52 in two UME trials as the FDA reviews an application for a decision by July ...